Puma Biotechnology (NASDAQ:PBYI) just reported results for the first quarter of 2024.
- Puma Biotechnology reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -22 cents.
- The company reported revenue of $43.80 million.
- This was 6.70% better than the analyst estimate for revenue of $41.05 million.